Russian Journal of Skin and Venereal DiseasesRussian Journal of Skin and Venereal DiseasesРоссийский журнал кожных и венерических болезней1560-95882412-9097Eco-Vector4293910.17816/dv42939ArticlesСтатьиReview ArticleAPPLICATION OF JANUS-KINASE INHIBITORS IN THE TREATMENT OF ALOPECIA AREATA (LITERATURE REVIEW)ПРИМЕНЕНИЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ В ЛЕЧЕНИИ ОЧАГОВОЙ АЛОПЕЦИИ (ОБЗОР ЛИТЕРАТУРЫ)LepekhovaAnfisa A.ЛепеховаАнфиса Александровна

MD, PhD, associate professor of the Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University), 119435, Moscow, Russian Federation

кандидат медицинских наук, доцент кафедры кожных венерических болезней ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет). 119991, г. Москва, Россия

anfisa.lepehova@yandex.ruChernyavskayaL. MЧернявскаяЛ. МDepartment of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)15042019221-2VOL 22, NO1-2 (2019)ТОМ 22, №1-2 (2019)616424082020Copyright ©; 2019, Eco-VectorCopyright ©; 2019, ООО "Эко-Вектор"2019Eco-VectorООО "Эко-Вектор"https://rjsvd.com/1560-9588/article/view/42939

Based on the analysis of data from modern foreign sources current information about using of Janus-kinase inhibitors, in particular, tofacitinid and ruxolitinid, for the treatment of alopecia areata in adults and children, in the presence of a lesion of the scalp and other areas (eyebrows, eyelashes) is shown. The information about the mechanism of action of Janus-kinase inhibitors, the efficacy and safety of their use, possible methods of use, prospects for further research in the treatment of alopecia areata using targeted drugs is presented. The pathogenetic rationale for the possibility of using this group of drugs for treating immune-mediated diseases, for instance, alopecia areata is described.

На основе анализа данных современных зарубежных источников литературы представлена актуальная информация об использовании ингибиторов янус-киназы, в частности, тофацитиниба и руксолитиниба, для лечения очаговой алопеции у взрослых и детей с поражением волосистой части головы, а также других участков (бровей, ресниц). Приведены сведения о механизме действия ингибиторов янус-киназы, об эффективности и безопасности их использования, возможных способах применения, перспективах дальнейших исследований в области лечения очаговой алопеции с помощью таргетных препаратов, а также патогенетическое обоснование возможности применения данной группы препаратов для лечения иммунноопосредованных заболеваний, к которым относится очаговая алопеция.

alopeciaalopecia areatatargeted drugsjanus kinase inhibitorstofacitinibruxolitinibreviewалопецияочаговая алопециятаргетные препаратыингибиторы янус-киназытофацитинибруксолитинибобзорJuarez-Rendon K.J., Rivera Sanchez G., Reyes-Lopez M.A., García-Ortiz J.E., Bocanegra-García V., Guardiola-Avila I., Altamirano-Garcia M.L. Alopecia Areata. Current situation and perspectives. Arch. Argent. Pediatr. 2017; 115(6): 404-11.Anzai A., Wang E.H.C., Lee E.Y., Aoki V., Christiano A.M. Pathomechanisms of immune-mediated alopecia. Int. Immunol. 2019; 31(7): 439-47.Liu L.Y., King B.A., Craiglow B.G. Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families. J. Am. Acad. Dermatol. 2018; 79(3): 556-8.Putterman E., Patel D.P., Andrade G., Harfmann K.L., Hogeling M., Cheng CE., et al. Severity of disease and quality of life in parents of children with alopecia areata, totalis, and universalis: A prospective, cross-sectional study. J. Am. Acad. Dermatol. 2019; 80(5): 1389-94.Iorizzo M., Tosti A. Emerging drugs for alopecia areata: JAK inhibitors. Expert Opin. Emerg. Drugs. 2018; 23(1): 77-81.Phan K., Ramachandran V., Sebaratnam D.F. Methotrexate for alopecia areata: a systematic review and meta-analysis. J. Am. Acad. Dermatol. 2019; 80(1): 120-7.Yun D., Silverberg N.B., Stein S.L. Alopecia areata treated with hydroxychloroquine: a retrospective study of nine pediatric cases. Pediatr. Dermatol. 2018; 35(3): 361-5.Wang E.H.C., Sallee B.N., Tejeda C.I., Christiano A.M. JAK Inhibitors for treatment of alopecia areata. J. Invest. Dermatol. 2018; 138(9): 1911-6.Kostovic K., Gulin S.J., Mokos Z.B., Ceovic R. Tofacitinib, an oral Janus kinase inhibitor: perspectives in dermatology. Curr. Med. Chem. 2017; 24(11): 1158-67.Vu M., Heyes C., Robertson S.J., Varigos G.A., Ross G. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo. Clin. Exp. Dermatol. 2017; 42(8): 942-4.Trueb R.M., Dias M.F.R.G. Alopecia areata: a comprehensive review of pathogenesis and management. Clin. Rev. Allergy Immunol. 2018; 54(1): 68-87.Choi B.Y. Hair-growth potential of ginseng and its major metabolites: a review on its molecular mechanisms. Inter. J. Mol. Sci. 2018; 19(9): E2703.de Jong A., Jabbari A., Dai Z., Xing L., Lee D., Li M.M., et al. High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata. JCI Insight. 2018; 3(19): pii: 121949.Schwartz D.M., Kanno Y., Villarino A., Ward M., Gadina M., O’Shea J.J. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 2017; 16(12): 843-62.Triyangkulsri K., Suchonwanit P. Role of Janus kinase inhibitors in the treatment of alopecia areata. Drug Des. Devel. Ther. 2018; 12: 2323-35.Damsky W., King B. A. JAK inhibitors in dermatology: the promise of a new drug class. J. Am. Acad. Dermatol. 2017; 76(4): 736-44.Samadi A., Ahmad Nasrollahi S., Hashemi A., Nassiri Kashani M., Firooz A. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. J. Dermatolog. Treat. 2017; 28(6): 476-83.Gilhar A., Keren A., Paus R. JAK inhibitors and alopecia areata. Lancet. 2019; 393(10169): 318-9.Ciechanowicz P., Rakowska A., Sikora M., Rudnicka L. JAK-inhibitors in dermatology. Current evidence and future applications. J. Dermatolog. Treat. 2018; 1-22. doi: 10.1080/09546634.2018.1546043Shreberk-Hassidim R., Ramot Y., Zlotogorski A. Janus kinase inhibitors in dermatology: A systematic review. J. Am. Acad. Dermatol. 2017; 76(4): 745-53.Ocampo-Garza J., Griggs J., Tosti A. New drugs under investigation for the treatment of alopecias. Exp. Opin. Investig. Drugs. 2019; 28(3): 275-84.Dhillon S. Tofacitinib. A Review in Rheumatoid Arthritis. Drugs. 2017; 77(18): 1987-2001.Tofacitinib. Drugs R.D. 2010; 10(4): 271-84.Falto-Aizpurua L., Choudhary S., Tosti A. Emerging treatments in alopecia. Expert Opin. Emerg. Drugs. 2014; 19(4): 545-56.Doker S., Dewenter M., El-Armouche A. Tofacitinib. Dtsch Med. Wochensch. 2014; 139(19): 1003-8.Phan K., Sebaratnam D. F. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J. Eur. Acad. Dermatol. Venereol. 2019; 33(5): 850-6.Kennedy Crispin M., Ko J.M., Craiglow B.G., Li S., Shankar G., Urban J.R., et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016; 1(15): e89776.Liu L.Y., King B.A. Tofacitinib for the treatment of severe alopecia areata in adults and adolescents. J. Investig. Dermatol. Symp. Proc. 2018; 19(1): 18-20.Serdaroglu S., Engin B., Celik U., Erkan E., Askın O., Oba C., Kutlubay Z. Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients. Dermatol. Ther. 2019; 32(3): e12844.Park H.S., Kim M.W., Lee J.S., Yoon H.S., Huh C.H., Kwon O., Cho S. Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: a case series. J. Am. Acad. Dermatol. 2017; 77(5): 978-80.Cheng M.W., Kehl A., Worswick S., Goh C. Successful treatment of severe alopecia areata with oral or topical tofacitinib. J. Drugs Dermatol. 2018; 17(7): 800-3.Jabbari A., Sansaricq F., Cerise J., Chen J.C., Bitterman A., Ulerio G., et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J. Invest. Dermatol. 2018; 138(7): 1539-45.Shivanna C.B., Shenoy C., Priya R.A. Tofacitinib (selective Janus kinase inhibitor 1 and 3): a promising therapy for the treatment of alopecia areata: a case report of six patients. Int. J. Trichology. 2018; 10(3): 103-7.Gupta A.K., Carviel J.L., Abramovits W. Efficacy of tofacitinib in treatment of alopecia universalis in two patients. J. Eur. Acad. Dermatol. Venereol. 2016; 30(8): 1373-8.Liu L.Y., King B.A. Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata. J. Am. Acad. Dermatol. 2019; 80(6): 1778-9.Craiglow B.G. Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes. JAAD Case Rep. 2018; 4(10): 988-9.Putterman E., Castelo-Soccio L. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. J. Am. Acad. Dermatol. 2018; 78(6): 1207-9.Castelo-Soccio L. Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis. J. Am. Acad. Dermatol. 2017; 76(4): 754-5.Dai Y.X., Chen C.C. Tofacitinib therapy for children with severe alopecia areata. J. Am. Acad. Dermatol. 2019; 80(4): 1164-6.Craiglow B.G., King B.A. Tofacitinib for the treatment of alopecia areata in preadolescent children. J. Am. Acad. Dermatol. 2018; 80(2): 568-70.Brown L., Skopit S. An excellent response to tofacitinib in a pediatric alopecia patient: a case report and review. J. Drugs Dermatol. 2018; 17(8): 914-7.Chiang A., Ortenzio F., Juhasz M.L.W. Yu V., Mesinkovska N.A. The balance of efficacy of tofacitinib and disease outbreaks in the treatment of alopecia is universal: a description of the case and a review of the literature. JAAD Case Rep. 2018; 4(7): 733-6.Almutairi N., Nour T.M., Hussain N.H. Janus kinase inhibitors for the treatment of severe alopecia areata: an Open-Label Comparative Study. Dermatology. 2019; 235(2): 130-6.